Bristol's Etopophos inj. approved May 17 for small-cell lung and testicular cancers.
BRISTOL ETOPOPHOS (ETOPOSIDE PHOSPHATE INJ.) APPROVED BY FDA May 17 for treatment of small-cell lung cancer and first-line and refractory testicular tumors. Etopophos is a water-soluble derivative of Bristol-Myers Squibb's VePesid (etoposide). The 100 mg vial became "approvable" at FDA Sept. 28.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth